Kezar Life Sciences Inc
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California. Show More...
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 4.18 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -0.69 -0.65 -2.26 -1.84 -1.74 Dividends USD Payout Ratio % * Shares Mil 13.0 13.0 10.0 19.0 23.0 Book Value Per Share * USD 5.97 4.5 3.21 Free Cash Flow Per Share * USD -0.94 -1.51 Return on Assets % -78.69 -25.95 -27.43 -34.37 -30.24 Financial Leverage (Average) 1.05 1.15 1.1 Return on Equity % -55.75 -37.56 -33.32 Return on Invested Capital % -59.5 -37.42 -33.22 Interest Coverage Current Ratio 16.11 35.26 32.91 13.52 18.69 Quick Ratio 14.97 34.39 32.19 13.03 18.22 Debt/Equity 0.07 0.04